ARA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ARA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-27), American Renal Associates Holdings's share price is $11.52. American Renal Associates Holdings's Book Value per Share for the quarter that ended in Sep. 2020 was $-2.29. Hence, American Renal Associates Holdings's PB Ratio of today is .
The historical rank and industry rank for American Renal Associates Holdings's PB Ratio or its related term are showing as below:
The historical data trend for American Renal Associates Holdings's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
American Renal Associates Holdings Annual Data | |||||||||||||||||
Trend | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | |||||||||
PB Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
American Renal Associates Holdings Quarterly Data | ||||||||||||||||||||
Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | |
PB Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
For the Diagnostics & Research subindustry, American Renal Associates Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, American Renal Associates Holdings's PB Ratio distribution charts can be found below:
* The bar in red indicates where American Renal Associates Holdings's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
American Renal Associates Holdings's PB Ratio for today is calculated as follows:
PB Ratio | = | Share Price | / | Book Value per Share (Q: Sep. 2020) |
= | 11.52 | / | -2.29 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PB Ratio | = | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock) |
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
American Renal Associates Holdings (NYSE:ARA) PB Ratio Explanation
Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Thank you for viewing the detailed overview of American Renal Associates Holdings's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Don E Williamson | officer: EVP, Chief Operating Officer | 500 CUMMINGS CENTER, SUITE 6550 BEVERLY MA 01915 |
Victoria Labriola | officer: VP and General Counsel | AMERICAN RENAL HOLDINGS, INC. 500 CUMMINGS CENTER, SUITE 6550 BEVERLY MA 01915 |
Joseph A Carlucci | director, officer: Chief Executive Officer | C/O AMERICAN RENAL ASSOCIATES HOLDINGS 500 CUMMINGS CENTER BEVERLY MA 01915 |
Syed T Kamal | director, officer: President | C/O AMERICAN RENAL ASSOCIATES HOLDINGS 500 CUMMINGS CENTER BEVERLY MA 01915 |
Jeremy Gelber | director | C/O CENTERBRIDGE PARTNERS, L.P., 375 PARK AVE, 12TH FLOOR, NEW YORK NY 10152 |
Christopher J Hocevar | director | 1601 CHESTNUT STREET SHAREHOLDER SERVICES TL05Y PHILADELPHIA PA 19192 |
Robert H Fish | director | C/O SKILLED HEALTHCARE 27442 PORTOLA PARKWAY, SUITE 200 FOOTHILL RANCH CA 92610 |
Michael Boxer | director | 9151 BOULEVARD 26 NORTH RICHLAND HILLS TX 76180 |
John M Jureller | director | FRONTIER COMMUNICATIONS, 401 MERRITT 7, NORWALK CT 06851 |
Thomas W Erickson | director | OMEGA HEALTHCARE INVESTORS INC, 900 VICTORS WAY STE. 350, AMM ARBER MI 48108 |
Jason Boucher | officer: Former VP & CFO | 500 CUMMINGS CENTER SUITE 6550 BEVERLY MA 01915 |
Mark Herbers | officer: Interim CFO and Interim CAO | 500 CUMMINGS CENTER, SUITE 6550, BEVERLY MA 01915 |
Michael Ray Costa | officer: VP and General Counsel | C/O AMERICAN RENAL ASSOCIATES HOLDINGS 500 CUMMINGS CENTER BEVERLY MA 01915 |
Patrick T Ryan | director | 401 EDGEWATER PLACE, SUITE 500, WAKEFIELD MA 01880 |
Jonathan L Wilcox | officer: VP & Chief Financial Officer | C/O AMERICAN RENAL ASSOCIATES HOLDINGS 500 CUMMINGS CENTER BEVERLY MA 01915 |
From GuruFocus
By Marketwired Marketwired • 10-19-2020
By PRNewswire PRNewswire • 10-02-2020
By Marketwired Marketwired • 10-06-2020
By ACCESSWIRE ACCESSWIRE • 10-09-2020
By Marketwired Marketwired • 06-27-2019
By Marketwired Marketwired • 07-19-2019
By PRNewswire PRNewswire • 10-02-2020
By ACCESSWIRE ACCESSWIRE • 10-05-2020
By Marketwired Marketwired • 08-06-2019
By ACCESSWIRE ACCESSWIRE • 10-07-2020
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.